Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1509558 | 0.97 | SNCA (0.58) | SNCATSHRLOXL2CA1CA2 | |
| Bromide SCHEMBL10773250 | 0.96 | SNCA (0.56) | SNCATSHRLOXL2CA1CA2 | |
| Bromide SCHEMBL9546910 | 0.95 | SNCA (0.55) | SNCATSHRLOXL2CA1CA2 | |
| Hydrochloric Acid SCHEMBL9493443 | 0.92 | CA1 (0.54) | SNCATSHRLOXL2CA1CA2 | |
| Bromide SCHEMBL5228525 | 0.85 | SLC7A5 (0.56) | SNCATSHRLOXL2CA1CA2 | |
| Bromide SCHEMBL9826440 | 0.85 | SMN1; SMN2 (0.58) | SNCACA1CA2RAB9AMAPT | |
| Bromide SCHEMBL31614317 | 0.84 | SLC7A5 (0.60) | SNCATSHRLOXL2RAB9AMAPT | |
| Bromide SCHEMBL1532873 | 0.84 | SLC7A5 (0.60) | SNCATSHRLOXL2RAB9AMAPT | |
| SCHEMBL10484476 | 0.84 | KMT2A (0.47) | SNCACA1CA2MAPTKMT2A | |
| SCHEMBL10484509 | 0.84 | POLB (0.46) | SNCATSHRLOXL2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2022-10-20 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10928728-B2 | Photoactivable nitrogen bases | BASF SE (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20210033972-A1 | PHOTOACTIVABLE NITROGEN BASES | BASF SE (DE) | 2021-02-04 | — | — | US | disclosed |
| CN-110698408-B | Antiviral drug for treatment of arenavirus infection | 奇尼塔病毒性出血热有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-0438261-A2 | Condensed heterocyclic glutamic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-07-24 | — | — | EP | disclosed |
| US-4997838-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0382078-A1 | Aromatic keto compounds, their preparation and medicinal as well as cosmetic preparations containing them | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
| EP-0334636-A2 | Pyrrolopyrimidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-09-27 | — | — | EP | disclosed |
| US-4782085-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4711900-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| US-4474804-A | 7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
| US-4439015-A | Disubstituted ethanes | HOFFMANN-LA ROCHE INC. (US) | 1984-03-27 | — | — | US | disclosed |
| US-4359568-A | LAMINATING RESINS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1982-11-16 | — | — | US | disclosed |
| US-4356298-A | FROM ACID CHLORIDE OF 1,4-BIS-P-CARBOXYPHENYL-1,3-BUTADIENE, ISOPHTHALOYL CHLORIDE, 4,4-DIPHENOXYDIPHENYL SULFONE, DIPHENYL ETHER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1982-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210033972-A1 | PHOTOACTIVABLE NITROGEN BASES | CBR1, ARNT, NR0B1 | SNCA 2054/4885TSHR 752/4885LOXL2 4458/4885 |
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | SNCA 1920/4885TSHR 3832/4885LOXL2 3005/4885 |
| US-10928728-B2 | Photoactivable nitrogen bases | CBR1, NR0B1, NR0B2 | SNCA 1887/4885TSHR 801/4885LOXL2 4330/4885 |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | SNCA 1920/4885TSHR 3832/4885LOXL2 3005/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SNCA 366/4885TSHR 2970/4885LOXL2 4642/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | SNCA 366/4885TSHR 2970/4885LOXL2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.